Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

被引：0
|
作者：
Roe, MT [1 ]
Sapp, SK [1 ]
Lincoff, AM [1 ]
机构：
[1] Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA
来源：
CLEVELAND CLINIC JOURNAL OF MEDICINE | 2000年 / 67卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.
引用
收藏
页码：131 / 140
页数：12
相关论文
共 50 条
  • [41] Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes
    McElwee, NE
    Johnson, ER
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (4A): : B39 - B43
  • [42] Impact of glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes without ST-elevation in the "real world"
    Monteiro, P
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 231A - 231A
  • [43] Trends of Use and Outcomes Associated With Glycoprotein-IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
    Gellatly, Rochelle M.
    Connell, Cia
    Tan, Christianne
    Andrianopoulos, Nick
    Ajani, Andrew E.
    Clark, David J.
    Nanayakkara, Shane
    Sebastian, Martin
    Brennan, Angela
    Freeman, Melanie
    O'Brien, Jessica
    Selkrig, Laura A.
    Reid, Christopher M.
    Duffy, Stephen J.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (05) : 414 - 422
  • [44] Glycoprotein IIb/IIIa inhibitors
    Herbert, ME
    Brewster, GS
    ANNALS OF EMERGENCY MEDICINE, 1999, 34 (03) : 407 - 408
  • [45] Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes
    Braunwald, E
    Maseri, A
    Armstrong, PW
    Califf, RM
    Gibler, WB
    Hamm, CW
    Simoons, ML
    Van de Werf, F
    AMERICAN HEART JOURNAL, 1998, 135 (04) : S56 - S66
  • [46] Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes
    Braunwald, E
    Maseri, A
    Armstrong, PW
    Califf, RM
    Gibler, WB
    Hamm, CW
    Simoons, ML
    Van de Werf, F
    EUROPEAN HEART JOURNAL, 1998, 19 : D22 - D30
  • [47] THE ROLE OF PLATELET GLYCOPROTEIN IIB/IIIA INHIBITORS IN CURRENT TREATMENT OF ACUTE CORONARY SYNDROME
    Sukhinina, T. S.
    Pevzner, D., V
    Mazurov, A., V
    Vlasik, T. N.
    Solovieva, N. G.
    Kostritca, N. S.
    Shakhnovich, R. M.
    Yavelov, I. S.
    KARDIOLOGIYA, 2022, 62 (04) : 64 - 72
  • [48] The TRACS score predicts benefit of upstream glycoprotein IIb/IIIa use in acute coronary syndromes
    Nathan, Sandeep
    Amin, Amit P.
    Calvin, James E., Jr.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A199 - A200
  • [49] Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: Gusto IV-ACS
    Cohen, M
    LANCET, 2001, 357 (9272): : 1899 - 1900
  • [50] Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease
    Auer, J
    Berent, R
    Lassnig, E
    Weber, T
    Maurer, E
    Eber, B
    HERZ, 2003, 28 (05) : 393 - 403
12345